Last Updated : September 24, 2023
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
TBC | calaspargase pegol | Acute lymphoblastic leukemia (ALL) | Active | |||
Truxima | Rituximab | Cancelled | ||||
Kivexa | Abacavir/lamivudine | HIV infection | List in a similar manner to other drugs in class | Complete | ||
TBC | abaloparatide | Osteoporosis, postmenopausal women | Withdrawn | |||
Orencia | Abatacept | Arthritis, Rheumatoid | List with clinical criteria and/or conditions | Complete | ||
Orencia | Abatacept | Arthritis, Juvenile Idiopathic & Juvenile Rheumatoid | List with clinical criteria and/or conditions | Complete | ||
Orencia | Abatacept | Arthritis, Rheumatoid | List in a similar manner | Complete | ||
Orencia | Abatacept | Arthritis, rheumatoid | List with clinical criteria and/or conditions | Complete | ||
Verzenio | Abemaciclib | Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Verzenio | abemaciclib | Adjuvant treatment of HR-positive, HER2-negative early breast cancer | Reimburse with clinical criteria and/or conditions | Complete |